We believe that in the case of Raynaud's syndrome such therapeutics can target the protein-protein interface between the filamin-2 and intracellular α2C-AR, but spare surface receptors expressed in other tissues, reducing side-effects. The gene discussed is FLNC; the disease is Raynaud disease.